AMPK—activating heterocyclic compounds and methods for using the same
US-9266856-B2 · Feb 23, 2016 · US
Modulation of N-acylethanolamine-hydrolysing acid amidase (NAAA) for disease treatment
US10364242B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10364242-B2 |
| Application number | US-201715803379-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 3, 2017 |
| Priority date | Nov 3, 2017 |
| Publication date | Jul 30, 2019 |
| Grant date | Jul 30, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Pharmaceutical compositions make up a compound acting as inhibitor of N-acylethanolamine-hydrolyzing acid amidase (NAAA), may be used for the therapeutical treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamines, particularly palmitoylethanolamide (PEA). The compound is used in methods of inhibiting NAAA and methods of therapeutical treatment and prevention of pain and inflammation.
First claim
Opening claim text (preview).
The invention claimed is: 1. The compound (endo)-3-(4-butylphenoxy)-8-[(3,5-dimethyl-1H-pyrazol-4-yl)sulphonyl]-8-azabicyclo[3.2.1]octane, pharmaceutically acceptable salts thereof, its hydrates, solvates and racemic mixtures. 2. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, excipient or diluent. 3. A method of treatment of pain and/or inflammatory disorders in which decreased levels of palmitoylethanolamine are associated with the disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition according to claim 1 . 4. A method according to claim 3 for treating acute inflammation or chronic inflammation. 5. A method according to claim 3 for treatment of acute pain, acute inflammatory pain, chronic inflammatory pain or neuropathic pain.
Assignees
Inventors
Classifications
- C07D451/06Primary
Oxygen atoms · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10364242B2 cover?
- Pharmaceutical compositions make up a compound acting as inhibitor of N-acylethanolamine-hydrolyzing acid amidase (NAAA), may be used for the therapeutical treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamines, particularly palmitoylethanolamide (PEA). The compound is used in methods of inhibiting NAAA and m…
- Who is the assignee on this patent?
- Fondazione St Italiano Tecnologia
- What technology area does this patent fall under?
- Primary CPC classification C07D451/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).